4bafe83e-072c-4042-bd3d-5f108391ed89
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 57
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.610
- FATTY_ACID_METABOLISM+0.420
- ADIPOGENESIS+0.360
- COAGULATION+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- P53_PATHWAY+0.310
- BILE_ACID_METABOLISM+0.300
- PEROXISOME+0.290
- XENOBIOTIC_METABOLISM+0.290
- APOPTOSIS+0.240
Top 10 suppressed
- G2M_CHECKPOINT-0.490
- MITOTIC_SPINDLE-0.450
- E2F_TARGETS-0.330
- MYC_TARGETS_V2-0.190
- PANCREAS_BETA_CELLS-0.170
- INTERFERON_ALPHA_RESPONSE-0.150
- UV_RESPONSE_DN-0.150
- UNFOLDED_PROTEIN_RESPONSE-0.140
- APICAL_SURFACE-0.100
- PROTEIN_SECRETION-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d25af392-21ad-4aa6-8669-34656bf71af5 | — | — | 0.826 |
| 2 | DRR168583 | — | — | 0.789 |
| 3 | TCGA-BH-A0DS-01A-11R-A056-07 | — | B | 0.782 |
| 4 | b2fa82e4-58f2-4dc6-ad6e-31886a1c9851 | — | — | 0.775 |
| 5 | SRR4195672 | — | — | 0.770 |
| 6 | SJEPD013_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.764 |
| 7 | SRR662978 | GTEX | — | 0.763 |
| 8 | TCGA-E9-A227-01A-11R-A157-07 | — | A | 0.758 |
| 9 | AUR-AFEC-TTM4-A-1-1-R-A742-41 | — | C | 0.744 |
| 10 | 4c075dfa-f213-4e97-9c4e-6aac7b8345c7 | — | — | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.610 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.420 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.360 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| PEROXISOME | 0.290 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.220 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.190 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |